XML 48 R35.htm IDEA: XBRL DOCUMENT
v3.26.1

Fair Value Disclosures (Tables) | 3 Months Ended
--- | ---
Feb. 28, 2026
Fair Value Disclosures [Abstract] |
Schedule of Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis |
| February 28, 2026 (1)
$ in thousands | Level 1 | Level 2 | Level 3 | Counterparty and Cash Collateral Netting (2) | Total
Assets: |  |  |  |  |
Financial instruments owned: |  |  |  |  |
Corporate equity securities .................................................................................. | $7,339,191 | $354,960 | $218,483 | $— | $7,912,634
Corporate debt securities ..................................................................................... | — | 5,401,094 | 50,755 | — | 5,451,849
Collateralized debt obligations and collateralized loan obligations ............... | — | 591,727 | 61,455 | — | 653,182
U.S. government and federal agency securities ................................................ | 2,524,173 | 67,934 | — | — | 2,592,107
Municipal securities .............................................................................................. | — | 556,120 | — | — | 556,120
Sovereign obligations ............................................................................................ | 928,270 | 1,038,133 | — | — | 1,966,403
Residential mortgage-backed securities ............................................................ | — | 2,123,844 | 6,134 | — | 2,129,978
Commercial mortgage-backed securities .......................................................... | — | 2,150 | 355 | — | 2,505
Other asset-backed securities ............................................................................. | — | 630,244 | 244,714 | — | 874,958
Loans and other receivables ................................................................................ | — | 2,156,054 | 85,396 | — | 2,241,450
Derivatives .............................................................................................................. | 155 | 7,079,249 | 14,691 | (5,186,913) | 1,907,182
Investments at fair value ...................................................................................... | — | 13,569 | 167,195 | — | 180,764
Total financial instruments owned, excluding Investments at fair value based on NAV .................................................................................................... | $10,791,789 | $20,015,078 | $849,178 | $(5,186,913) | $26,469,132
Securities received as collateral .......................................................................... | $393,867 | $— | $— | $— | $393,867
Liabilities: |  |  |  |  |
Financial instruments sold, not yet purchased: |  |  |  |  |
Corporate equity securities .................................................................................. | $6,457,960 | $119,236 | $167 | $— | $6,577,363
Corporate debt securities ..................................................................................... | — | 3,196,057 | 555 | — | 3,196,612
Collateralized debt obligations and collateralized loan obligations ............... | — | 1,000 | — | — | 1,000
U.S. government and federal agency securities ................................................ | 1,590,146 | 16 | — | — | 1,590,162
Municipal securities .............................................................................................. | — | 88 | — | — | 88
Sovereign obligations ............................................................................................ | 688,027 | 837,099 | — | — | 1,525,126
Residential mortgage-backed securities ............................................................ | — | 2,041 | — | — | 2,041
Loans ....................................................................................................................... | — | 264,838 | 921 | — | 265,759
Derivatives .............................................................................................................. | 56 | 6,858,114 | 43,253 | (5,600,436) | 1,300,987
Total financial instruments sold, not yet purchased ....................................... | $8,736,189 | $11,278,489 | $44,896 | $(5,600,436) | $14,459,138
Other secured financings ...................................................................................... | $— | $412,338 | $11,685 | $— | $424,023
Obligation to return securities received as collateral ....................................... | 393,867 | — | — | — | 393,867
Long-term debt ....................................................................................................... | — | 2,662,691 | 1,024,067 | — | 3,686,758
(1)Excludes investments at fair value based on net asset value (“NAV”) of $1.61 billion at February 28, 2026 by level within the fair value hierarchy. (2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
| November 30, 2025 (1)
$ in thousands | Level 1 | Level 2 | Level 3 | Counterparty and Cash Collateral Netting (2) | Total
Assets: |  |  |  |  |
Financial instruments owned: |  |  |  |  |
Corporate equity securities .................................................................................. | $7,664,824 | $249,847 | $218,853 | $— | $8,133,524
Corporate debt securities ..................................................................................... | — | 5,367,201 | 37,578 | — | 5,404,779
Collateralized debt obligations and collateralized loan obligations ............... | — | 645,798 | 40,187 | — | 685,985
U.S. government and federal agency securities ................................................ | 2,342,718 | 106,633 | — | — | 2,449,351
Municipal securities .............................................................................................. | — | 563,994 | — | — | 563,994
Sovereign obligations ............................................................................................ | 860,832 | 815,722 | — | — | 1,676,554
Residential mortgage-backed securities ............................................................ | — | 1,827,092 | 6,663 | — | 1,833,755
Commercial mortgage-backed securities .......................................................... | — | 10,458 | 348 | — | 10,806
Other asset-backed securities ............................................................................. | — | 909,474 | 133,001 | — | 1,042,475
Loans and other receivables ................................................................................ | — | 2,111,517 | 127,720 | — | 2,239,237
Derivatives .............................................................................................................. | 72 | 5,519,463 | 10,311 | (3,705,764) | 1,824,082
Investments at fair value ...................................................................................... | — | 13,567 | 163,107 | — | 176,674
Total financial instruments owned, excluding Investments at fair value based on NAV .................................................................................................... | $10,868,446 | $18,140,766 | $737,768 | $(3,705,764) | $26,041,216
Securities received as collateral .......................................................................... | $200,495 | $— | $— | $— | $200,495
Liabilities: |  |  |  |  |
Financial instruments sold, not yet purchased: |  |  |  |  |
Corporate equity securities .................................................................................. | $5,571,534 | $47,631 | $155 | $— | $5,619,320
Corporate debt securities ..................................................................................... | — | 2,761,794 | 3,720 | — | 2,765,514
Collateralized debt obligations and collateralized loan obligations ............... | — | 627 | — | — | 627
U.S. government and federal agency securities ................................................ | 1,913,403 | 4 | — | — | 1,913,407
Sovereign obligations ............................................................................................ | 796,564 | 540,555 | — | — | 1,337,119
Loans ....................................................................................................................... | — | 184,391 | 9,757 | — | 194,148
Derivatives .............................................................................................................. | 24 | 5,429,227 | 45,953 | (3,985,187) | 1,490,017
Total financial instruments sold, not yet purchased ....................................... | $8,281,525 | $8,964,229 | $59,585 | $(3,985,187) | $13,320,152
Other secured financings ...................................................................................... | $— | $412,510 | $13,454 | $— | $425,964
Obligation to return securities received as collateral ...................................... | 200,495 | — | — | — | 200,495
Long-term debt ....................................................................................................... | — | 2,671,485 | 1,063,358 | — | 3,734,843
(1)Excludes investments at fair value based on NAV of $1.68 billion at November 30, 2025 by level within the fair value hierarchy. (2)Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Schedule of Investments Measured at Fair Value Based on Net Asset Value Per Share | Information about our investments in entities that have the characteristics of an investment company:
| February 28, 2026
$ in thousands | Fair Value (1) | Unfunded Commitments | Redemption Frequency | Redemption Notice Period
Hedge Funds (2) .............. | $781,873 | $— | Quarterly (41%) Monthly (39%) N/R (20%) | 45 - 90 days 45 - 60 days N/R
Private Equity Funds (3) .............. | 69,295 | 23,473 | N/R (100%) | N/R
Credit Funds (4) .............. | 497,569 | 23,847 | Quarterly (53%) Monthly (2%) N/R (45%) | 90 days 30 days N/R
Real Estate and Other Funds (5) .... | 261,589 | 111,269 | Quarterly (12%) N/R (88%) | 90 days N/R
Total ...................... | $1,610,326 | $158,589 |  |
| November 30, 2025
$ in thousands | Fair Value (1) | Unfunded Commitments | Redemption Frequency | Redemption Notice Period
Hedge Funds (2) ............ | $888,880 | $— | Quarterly (42%) Monthly (41%) N/R (17%) | 45 - 90 days 45 - 60 days N/R
Private Equity Funds (3) ............ | 66,476 | 26,828 | N/R (100%) | N/R
Credit Funds (4) | 490,321 | 23,847 | Quarterly (56%) Monthly (2%) N/R (42%) | 90 days 30 days N/R
Real Estate and Other Funds (5) . | 235,846 | 114,872 | Quarterly (19%) N/R (81%) | 90 days N/R
Total ................... | $1,681,523 | $165,547 |  |
N/R - Not redeemable (1)Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements. (2)Includes investments in hedge funds that invest, long and short, primarily in both public and private equity securities in domestic and international markets, commodities and multi-asset securities. (3)Includes investments in equity funds that invest in the equity of various U.S. and foreign private companies in a broad range of industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are primarily expected to be liquidated in approximately one to nine years. (4)Primarily includes investments in funds that invest in: •Distressed and special situations long/short credit strategies across sectors and asset types; •Short-term trade receivables and payables that are expected to generally be outstanding between 90 to 120 days; and •Distressed and event-driven opportunities across structured credit, opportunistic credit, and private credit. (5)Primarily includes investments in corporate real estate strategies focused on buying or building real estate businesses and investments in venture capital funds.
Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis Unobservable Input Reconciliation |
|  |  |  |  |  |  |  |  | For instruments still held at February 28, 2026, changes in unrealized gains/(losses) included in:
$ in thousands | Balance at November 30, 2025 | Total gains/ losses (realized and unrealized) (1) | Purchases | Sales | Settlements | Issuances | Net transfers into/ (out of) Level 3 | Balance at February 28, 2026 | Earnings (1) | Other comprehensive income (1)
Assets: |  |  |  |  |  |  |  |  |  |
Financial instruments owned: |  |  |  |  |  |  |  |  |  |
Corporate equity securities ... | $218,853 | $(6,089) | $12,452 | $(3,342) | $(397) | $— | $(2,994) | $218,483 | $(6,456) | $—
Corporate debt securities ...... | 37,578 | 1,716 | 66,717 | (66,617) | (629) | — | 11,990 | 50,755 | (579) | —
CDOs and CLOs ....................... | 40,187 | (7,026) | 39,519 | (11,654) | — | — | 429 | 61,455 | (5,505) | —
RMBS ........................................ | 6,663 | (127) | — | — | (402) | — | — | 6,134 | (127) | —
CMBS ........................................ | 348 | 7 | — | — | — | — | — | 355 | 7 | —
Other ABS ................................. | 133,001 | (45,135) | 119,288 | (7,909) | (2,919) | — | 48,388 | 244,714 | (45,257) | —
Loans and other receivables . | 127,720 | (973) | 214,243 | (207,158) | (790) | — | (47,646) | 85,396 | 2,488 | —
Investments at fair value ....... | 163,107 | 4,636 | 250 | (23) | (775) | — | — | 167,195 | 3,895 | —
Liabilities: |  |  |  |  |  |  |  |  |  |
Financial instruments sold, not yet purchased: |  |  |  |  |  |  |  |  |  |
Corporate equity securities ... | $155 | $12 | $— | $— | $— | $— | $— | $167 | $(12) | $—
Corporate debt securities ...... | 3,720 | 192 | — | — | — | — | (3,357) | 555 | (192) | —
CDOs and CLOs ....................... | — | 3 | — | — | (3) | — | — | — | — | —
Loans ........................................ | 9,757 | (40) | (697) | 725 | — | — | (8,824) | 921 | (1,687) | —
Net derivatives (2) ................... | 35,642 | (11,191) | (5,332) | — | 1,484 | 7,638 | 321 | 28,562 | 7,430 | —
Other secured financings ....... | 13,454 | (144) | — | 120 | (1,745) | — | — | 11,685 | 134 |
Long-term debt ........................ | 1,063,358 | (18,984) | — | — | (23,695) | 6,737 | (3,349) | 1,024,067 | (34,884) | 53,868
(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income. (2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased —Derivatives.
|  |  |  |  |  |  |  |  | For instruments still held at February 28, 2025, changes in unrealized gains/(losses) included in:
$ in thousands | Balance at November 30, 2024 | Total gains/ losses (realized and unrealized) (1) | Purchases | Sales | Settlements | Issuances | Net transfers into/ (out of) Level 3 | Balance at February 28, 2025 | Earnings (1) | Other comprehensive income (1)
Assets: |  |  |  |  |  |  |  |  |  |
Financial instruments owned: |  |  |  |  |  |  |  |  |  |
Corporate equity securities ....................... | $239,364 | $2,864 | $1,703 | $(1,016) | $— | $— | $(30,506) | $212,409 | $5,300 | $—
Corporate debt securities | 24,931 | (1,002) | 6,753 | (895) | — | — | (3,862) | 25,925 | (1,248) | —
CDOs and CLOs ................. | 63,976 | (4,646) | 17,177 | (9,981) | — | — | 5,301 | 71,827 | (4,664) | —
Sovereign obligations ....... | 172 | 2 | — | (174) | — |  |  | — | (1) | —
RMBS .................................. | 7,714 | (167) | — | — | (21) | — | — | 7,526 | (59) | —
CMBS .................................. | 477 | (6) | — | — | — | — | — | 471 | — | —
Other ABS ........................... | 103,214 | (1,889) | 54,165 | (4,709) | (2,312) | — | (1,150) | 147,319 | (1,318) | —
Loans and other receivables .................... | 152,586 | (949) | 78,763 | (53,590) | (9,170) | — | (13,876) | 153,764 | (1,545) | —
Investments at fair value . | 137,865 | 393 | 21,288 | — | (1,665) | — | — | 157,881 | 393 | —
Liabilities: |  |  |  |  |  |  |  |  |  |
Financial instruments sold, not yet purchased: |  |  |  |  |  |  |  |  |  |
Corporate equity securities ....................... | $208 | $(72) | $— | $454 | $— | $— | $— | $590 | $72 | $—
Corporate debt securities | 165 | (40) | (383) | 1,025 | — | — | 346 | 1,113 | 24 | —
RMBs .................................. | — | — | — | 15 | — | — | — | 15 | — | —
CMBS .................................. | 1,153 | 1 | — | 35 | — | — | (35) | 1,154 | (1) | —
Loans .................................. | 16,864 | 301 | (1,917) | 75 | — | — | (14,475) | 848 | 89 | —
Net derivatives (2) ............. | 22,286 | (16,020) | — | 22,588 | (279) | 299 | 13,202 | 42,076 | 14,559 | —
Other secured financings . | 14,884 | (1,938) | — | — | (241) | — | — | 12,705 | 1,938 | —
Long-term debt .................. | 821,903 | (55,177) | — | — | — | 124,554 | (30,596) | 860,684 | 29,428 | 25,749
(1)Realized and unrealized gains/losses are primarily reported in Principal transactions revenues. Changes in instrument-specific credit risk related to structured notes within Long-term debt are presented net of tax in our Consolidated Statements of Comprehensive Income. (2)Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
Schedule of Fair Value Inputs Assets and Liabilities Quantitative Information Table |
February 28, 2026
Financial Instruments Owned | Fair Value (in thousands) | Valuation Technique | Significant Unobservable Input(s) | Input / Range | Weighted Average
Corporate equity securities ..................... | $218,483 |  |  |  |  |  |
Non-exchange-traded securities | Market approach | Price | $0 | - | $1,115 | $90
| Volatility benchmarking | Volatility | 45% | - | 49% | 48%
Corporate debt securities ........................ | $50,755 | Market approach | Price | $58 | - | $122 | $92
|  | Discounted cash flows | Discount rate/yield | 22% | - | 26% | 24%
CDOs and CLOs .......................................... | $31,965 | Discounted cash flows | Constant prepayment rate | 15% | - | 20% | 16%
|  |  | Constant default rate | 2% | —
|  |  | Loss severity | 30% | —
|  |  | Discount rate/yield | 13% | - | 15% | 14%
|  | Market approach | Price | $98 | - | $118 | $101
RMBS ........................................................... | $6,134 | Discounted cash flows | Constant prepayment rate | 10% | —
|  |  | Constant default rate | 0.5% | —
|  |  | Loss severity | 45% | —
|  |  | Discount rate/yield | 20% | —
Other ABS ................................................... | $242,697 | Discounted cash flows | Discount rate/yield | 10.9% | - | 15.8% | 15.2%
|  |  | Cumulative loss rate | 10.5% | - | 17.4% | 16.5%
|  |  | Duration (years) | 1.1 | - | 1.5 | 1.2
|  | Market approach | Price | $118 | - | $135 | $132
|  | Scenario analysis | Estimated recovery percentage | 64% | - | 69% | 68%
Loans and other receivables ................... | $85,396 | Market approach | Price | $8 | - | $118 | $106
|  | Scenario analysis | Estimated recovery percentage | 18% | - | 222% | 92%
Derivatives .................................................. | $11,104 |  |  |  |  |  |
Embedded options |  | Market approach | Basis points upfront | 0.3 | - | 0.5 | 0.4
Equity options |  | Volatility benchmarking | Volatility | 51% | —
Investments at fair value .......................... | $161,250 |  |  |  |  |  |
Private equity securities |  | Market approach | Price | $0 | - | $27,989 | $2,838
|  |  | Discount rate/yield | 28% | —
|  |  | Estimated revenue | $29,760,909 | —
Financial Instruments Sold, Not Yet Purchased: |  |  |  |  |  |
Derivatives .................................................. | $43,253 |  |  |  |  |  |
Equity options |  | Volatility benchmarking | Volatility | 39% | - | 67% | 53%
Embedded options |  | Market approach | Basis points upfront | 7.2 | - | 19.9 | 12.8
Other secured financings ......................... | $11,685 | Scenario analysis | Estimated recovery percentage | 74% | - | 100% | 95%
|  | Market approach | Price | $117 | - | $118 | $118
Long-term debt .......................................... | $1,024,067 |  |  |  |  |  |
Structured notes |  | Market approach | Price | $70 | - | $120 | $100
November 30, 2025
Financial Instruments Owned | Fair Value (in thousands) | Valuation Technique | Significant Unobservable Input(s) | Input / Range | Weighted Average
Corporate equity securities ..................... | $218,853 |  |  |  |  |  |
Non-exchange-traded securities | Market approach | Price | $0 | - | $486 | $85
|  | Volatility benchmarking | Volatility | 44% | - | 48% | 47%
Corporate debt securities ........................ | $37,578 | Market approach | Price | $49 | - | $121 | $72
|  | Discounted cash flows | Discount rate/yield | 18% | - | 20% | 19%
|  | Scenario analysis | Estimated recovery percentage | 30% | —
CDOs and CLOs .......................................... | $25,824 | Discounted cash flows | Constant prepayment rate | 20% | —
|  |  | Constant default rate | 2% | —
|  |  | Loss severity | 30% | —
|  |  | Discount rate/yield | 17% | —
|  | Market approach | Price | $98 | - | $100 | $99
RMBS ........................................................... | $6,663 | Discounted cash flows | Constant prepayment rate | 12% | —
|  |  | Constant default rate | 0.3% | —
|  |  | Loss severity | 20% | —
|  |  | Discount rate/yield | 15% | —
Other ABS ................................................... | $129,693 | Discounted cash flows | Discount rate/yield | 15.5% | - | 15.7% | 15.6%
|  |  | Cumulative loss rate | 16.0% | - | 16.4% | 16.2%
|  |  | Duration (years) | 1.1 | - | 1.2 | 1.1
|  | Market approach | Price | $116 | - | $133 | $130
|  | Scenario analysis | Estimated recovery percentage | 66% | —
Loans and other receivables ................... | $127,720 | Market approach | Price | $67 | - | $129 | $97
|  | Scenario analysis | Estimated recovery percentage | 8% | - | 100% | 35%
Derivatives .................................................. | $6,094 |  |  |  |  |  |
Embedded options |  | Market approach | Basis points upfront | 0.4 | - | 0.5 | 0.5
Equity options |  | Volatility benchmarking | Volatility | 34% | —
Investments at fair value .......................... | $157,162 |  |  |  |  |  |
Private equity securities |  | Market approach | Price | $0 | - | $27,989 | $2,722
|  |  | Discount rate/yield | 28% | —
|  |  | Estimated revenue | $29,818,082 | —
Financial Instruments Sold, Not Yet Purchased: |  |  |  |  |  |
Corporate debt securities ........................ | $3,720 | Scenario analysis | Estimated recovery percentage | 30% | —
Loans ........................................................... | $9,757 | Market approach | Price | $100 | - | $129 | $117
|  | Scenario analysis | Estimated recovery percentage | 30% | —
Derivatives .................................................. | $45,953 |  |  |  |  |  |
Equity options |  | Volatility benchmarking | Volatility | 34% | - | 61% | 58%
Embedded options |  | Market approach | Basis points upfront | 0.0 | - | 21.0 | 13.3
Other secured financings ......................... | $13,454 | Scenario analysis | Estimated recovery percentage | 74% | - | 100% | 96%
|  | Market approach | Price | $114 | - | $117 | $115
Long-term debt .......................................... | $1,063,358 |  |  |  |  |  |
Structured notes |  | Market approach | Price | $72 | - | $120 | $101
Schedule of Fair Value Option Gains (Losses) and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables | Fair value option gains (losses):
| Three Months Ended February 28,
$ in thousands | 2026 | 2025
Financial instruments owned: |  |
Loans and other receivables (1) ............................................. | $(28,722) | $13,283
Other secured financings: |  |
Other changes in fair value (1) ................................................ | $(309) | $1,938
Long-term debt: |  |
Changes in instrument-specific credit risk (2) ...................... | $77,896 | $37,898
Other changes in fair value (1) ................................................ | (58,916) | 16,944
(1)Other changes in fair value are included in Principal transactions revenues. (2)Changes in fair value of structured notes related to instrument-specific credit risk are presented net of tax in our Consolidated Statements of Comprehensive Income. Difference between contractual principal and fair value (1):
$ in thousands | February 28, 2026 | November 30, 2025
Financial instruments owned: |  |
Loans and other receivables (2) ................................ | $2,219,310 | $2,378,747
Loans and other receivables on nonaccrual status and/or 90 days or greater past due (2) ..... | 420,878 | 319,394
Loans and other receivables 90 days or greater past due (2) .............................................. | 70,748 | 100,300
Long-term debt ............................................................ | 222,020 | 166,273
Other secured financings ........................................... | (4,798) | 237
(1)Amounts indicate contractual principal greater than or (less than) fair value. (2)Interest income is recognized separately from other changes in fair value and is included in Interest revenues. Fair value of loans and other receivables on nonaccrual status:
$ in thousands | February 28, 2026 | November 30, 2025
Financial instruments owned: |  |
Loans and other receivables on nonaccrual status and/or 90 days or greater past due ........................... | $109,143 | $119,900
Loans and other receivables 90 days or greater past due ..................................................................... | 66,657 | 47,000

X
- Definition Reconciliation of beginning Level 3 assets and liabilities to ending Level 3 assets and liabilities (specifically disaggregating purchases, sales, settlements, issuances, transfers to Level 3 and transfers out of Level 3). + References No definition available. + Details
Name: | jef_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTableTableTextBlock
Namespace Prefix: | jef_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quantitative information about significant unobservable inputs used in the fair value measurement of Level 3 financial assets and liabilities, including valuation technique and range of inputs + References No definition available. + Details
Name: | jef_FairValueInputsAssetsAndLiabilitiesQuantitativeInformationTableTableTextBlock
Namespace Prefix: | jef_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 54B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482134/820-10-35-54B Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A + Details
Name: | us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information about asset and liability measured at fair value under fair value option. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 10 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 + Details
Name: | us-gaap_FairValueOptionQuantitativeDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration